NKGen Biotech to Present on Troculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy Forum
NKGen Biotech chairman and CEO Paul Y. Song will present on the company's lead investigational program, troculeucel, at the 4th Great Bay Cell and Gene Therapy Forum in Guangzhou, China, on September 23, 2026. The presentation will cover troculeucel's proposed mechanism of action, neuroinflammatory and protein biomarker changes observed in cerebrospinal fluid, and clinical experience in Alzheimer's disease patients, with Parkinson's disease and frontotemporal dementia named as potential areas for further evaluation.
Key figures
- Drug Name
- troculeucel
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.